AllCells Releases New Line of Bioservices

EMERYVILLE, Calif., Jan. 3, 2013 /PRNewswire/ --AllCells LLC, a leading provider of healthy & diseased hematopoietic tissues and related services to the global life science industry is proud to announce the release of a new line of Bioservices. The CRO type of Bioservices will be focusing on drug discovery, preclinical research, drug toxicity assays, and other life science research applications.

Immunoassays

Stem Cell Assays

Flow Cytometry Services

Tissue Culture Services

Protein Analysis

Genotyping

For a complete list and more in-depth descriptions, please refer to the AllCells 2013-2014 Product Catalog.

"The introduction of these CRO type of Bioservices provide essential components of hematological cell-based assays commonly used in the work-flow of drug development based research projects," commented Dr. Basha Stankovich, Manager of Bioservices. Dr. Jack Zhai, VP of Sales & Marketing added, "These Bioservices offerings combine with our 20 years of experience in hematology, which provides our customers with a range of cell-based assays within the academia/non-profit market segment."

For more information about our Bioservices, please visit http://www.allcells.com/bioservices/. Full press release available here: http://www.allcells.com/blog/allcells-releases-new-line-of-bioservices/ .

The rest is here:
AllCells Releases New Line of Bioservices